Drug evaluation: Agomelatine targets a range of major depressive disorder symptoms

Margarita L. Dubocovich

Drug evaluation: Agomelatine targets a range of major depressive disorder symptoms

Margarita L. Dubocovich

Pharmacology and Toxicology

Research output: Contribution to journal › Review article › peer-review

49 Scopus citations

Abstract

Servier, and US licensee Novartis AG, are developing the oral melatonin MT₁ and MT₂ agonist and 5-HT_2B and 5-HT_2C antagonist agomelatine as a once-daily treatment for major depressive disorder (MDD) and its symptoms, particularly anxiety, and sleep and circadian disturbances. Phase III trials have been completed and a registration dossier has been submitted to the EMEA in Western Europe.

Original language	English
Pages (from-to)	670-680
Number of pages	11
Journal	Current Opinion in Investigational Drugs
Volume	7
Issue number	7
State	Published - Jul 2006

Cite this

@article{c5dfe31c2be748b6a221fc66a1e9c130,

title = "Drug evaluation: Agomelatine targets a range of major depressive disorder symptoms",

abstract = "Servier, and US licensee Novartis AG, are developing the oral melatonin MT1 and MT2 agonist and 5-HT2B and 5-HT2C antagonist agomelatine as a once-daily treatment for major depressive disorder (MDD) and its symptoms, particularly anxiety, and sleep and circadian disturbances. Phase III trials have been completed and a registration dossier has been submitted to the EMEA in Western Europe.",

author = "Dubocovich, \{Margarita L.\}",

year = "2006",

month = jul,

language = "English",

volume = "7",

pages = "670--680",

journal = "Current Opinion in Investigational Drugs",

issn = "1472-4472",

publisher = "Thomson Scientific Ltd.",

number = "7",

}

TY - JOUR

T1 - Drug evaluation

T2 - Agomelatine targets a range of major depressive disorder symptoms

AU - Dubocovich, Margarita L.

PY - 2006/7

Y1 - 2006/7

N2 - Servier, and US licensee Novartis AG, are developing the oral melatonin MT1 and MT2 agonist and 5-HT2B and 5-HT2C antagonist agomelatine as a once-daily treatment for major depressive disorder (MDD) and its symptoms, particularly anxiety, and sleep and circadian disturbances. Phase III trials have been completed and a registration dossier has been submitted to the EMEA in Western Europe.

AB - Servier, and US licensee Novartis AG, are developing the oral melatonin MT1 and MT2 agonist and 5-HT2B and 5-HT2C antagonist agomelatine as a once-daily treatment for major depressive disorder (MDD) and its symptoms, particularly anxiety, and sleep and circadian disturbances. Phase III trials have been completed and a registration dossier has been submitted to the EMEA in Western Europe.

UR - https://www.scopus.com/pages/publications/33745795154

M3 - Review article

C2 - 16869122

AN - SCOPUS:33745795154

SN - 1472-4472

VL - 7

SP - 670

EP - 680

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

IS - 7

ER -

Drug evaluation: Agomelatine targets a range of major depressive disorder symptoms

Abstract

Other files and links

Fingerprint

Cite this